Q2 2026 net sales rose 16% year-over-year, with net income up 6% and gross margin improving to 42.6%. Growth was driven by all regions and product lines, including contributions from the My Medic acquisition, while management expects further profitability improvements as cost initiatives take hold.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.